Show simple item record

dc.contributor.authorBakuridze, Kakhi
dc.contributor.authorSavli, Evren
dc.contributor.authorGongadze, Niko
dc.contributor.authorBas, Duygu Belkis
dc.contributor.authorGepdiremen, Akcahan
dc.date.accessioned2020-06-21T15:08:03Z
dc.date.available2020-06-21T15:08:03Z
dc.date.issued2009
dc.identifier.issn0020-7454
dc.identifier.issn1563-5279
dc.identifier.urihttps://doi.org/10.1080/00207450902787165
dc.identifier.urihttps://hdl.handle.net/20.500.12712/18920
dc.descriptionWOS: 000270737300012en_US
dc.descriptionPubMed: 19922382en_US
dc.description.abstractIn the present study we investigated the effects of mixed imidazoline-1 and alpha(2)-adrenoceptor agonist, moxonidine, in glutamate-induced neurotoxicity in frontal cortical cell cultures of rat pups by dye exclusion test. Also, phosphorylated p38 mitogen activated protein kinases (p-p38 MAPK) levels were determined from rat frontal cortical tissue homogenates by two dimensional gel electrophoresis and semidry western blotting. Glutamate at a concentration of 10(-6) M was found neurotoxic when applied for 16 hr in cell cultures. Dead cell mean scores were 12.8 +/- 0.5 for control and 52.3 +/- 4.8 for glutamate (p<.001). On the other hand, p-p38 MAPK levels start to increase at a glutamate concentration of 10(-7) M for 20 min application. Moxonidine was found to have an U-shape neuroprotective effect in glutamate-induced neurotoxicity in neuronal cell culture experiments. Even though moxonidine did not induce neurotoxicity alone between the doses of 10(-8) to 10(-4) M concentrations in cell culture series, it caused the reduction of glutamate-induced dead cell population 23.07 +/- 3.6% in 10(-6) M and 26.7 +/- 2.1% in 10(-5) M concentrations (p<.001 for both, in respect to control values). The protective effect of moxonidine was confirmed in 10(-8) and 10-7 M, but not in higher concentrations in glutamate neurotoxicity in gel electrophoresis and western blotting of p-p38 MAPK levels. In addition to other studies that revealed an antihypertensive feature of moxonidine, we demonstrated a possible partial neuroprotective role in lower doses for it in glutamate-mediated neurotoxicity model.en_US
dc.description.sponsorshipTUBITAK NATO PCA2Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)en_US
dc.description.sponsorshipDr. Kakhi Bakuridze was supported by a grant received from TUBITAK NATO PCA2 program.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.isversionof10.1080/00207450902787165en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectglutamateen_US
dc.subjectimidazoline receptorsen_US
dc.subjectmoxonidineen_US
dc.subjectneurotoxicityen_US
dc.titleProtection in Glutamate-Induced Neurotoxicity By Imidazoline Receptor Agonist Moxonidineen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume119en_US
dc.identifier.issue10en_US
dc.identifier.startpage1705en_US
dc.identifier.endpage1717en_US
dc.relation.journalInternational Journal of Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record